Publications by authors named "R Cappelli"
Article Synopsis
- The study evaluates the risk of short-term death in patients on anticoagulant treatment who experience major bleeding (MB) as defined by the International Society of Thrombosis and Haemostasis (ISTH).
- It identifies key predictors of death, such as a Glasgow coma scale (GCS) score below 14 and shock at the time of admission, while noting that other factors like the site of bleeding and hemoglobin levels were not significant.
- The findings support a new classification system for MBs that categorizes them into "serious," "severe," and "life-threatening" based on their associated risk of death within 30 days.
The association between preceding treatment with antiplatelet agents (APs), vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) and mortality after intracerebral hemorrhage (ICH) remains unclear. The aim of this multicenter, prospective cohort study was to assess the risk for death after ICH in consecutive patients who were on treatment with APs, VKAs, DOACs, or no antithrombotic agent. The primary outcome was in-hospital death by day 30.
View Article and Find Full Text PDFThe impact of residual pulmonary obstruction on the outcome of patients with pulmonary embolism is uncertain.We recruited 647 consecutive symptomatic patients with a first episode of pulmonary embolism, with or without concomitant deep venous thrombosis. They received conventional anticoagulation, were assessed for residual pulmonary obstruction through perfusion lung scanning after 6 months and then were followed up for up to 3 years.
View Article and Find Full Text PDFBackground: The recanalization rate in patients with deep venous thrombosis (DVT) of the legs treated with the direct oral anticoagulants (DOAC) is unknown.
Methods: In an Italian cohort, we investigated the rate of residual vein thrombosis (RVT) after three and/or six months in 352 patients with proximal DVT who had been treated with the DOACs as a stand-alone therapy or lead-in parenteral anticoagulants, and compared it to that recorded in a historical cohort of 1094 patients in which vitamin K antagonists (VKAs) had been employed. In both cohorts, RVT was defined as the ultrasound persistence of thrombotic material resulting in a diameter of at least 4mm of incompressibility of the proximal veins.